RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model
AUTOR(ES)
Harper, Scott Q.
FONTE
National Academy of Sciences
RESUMO
Huntington's disease (HD) is a fatal, dominant neurogenetic disorder. HD results from polyglutamine repeat expansion (CAG codon, Q) in exon 1 of HD, conferring a toxic gain of function on the protein huntingtin (htt). Currently, no preventative treatment exists for HD. RNA interference (RNAi) has emerged as a potential therapeutic tool for treating dominant diseases by directly reducing disease gene expression. Here, we show that RNAi directed against mutant human htt reduced htt mRNA and protein expression in cell culture and in HD mouse brain. Importantly, htt gene silencing improved behavioral and neuropathological abnormalities associated with HD. Our data provide support for the further development of RNAi for HD therapy.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=556303Documentos Relacionados
- Neuropathological diagnosis and CAG repeat expansion in Huntington's disease.
- Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
- Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease
- The EEG in Huntington's chorea: a clinical and neuropathological study
- Knock-In Mouse Models of Huntington's Disease
